Want to see AUTL full AI Analyst Report?
Top Page
Autolus Therapeutics
(NASDAQ:AUTL)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▼(-36.44% Downside)
Action:Reiterated
Date:10/17/26
The score is held back primarily by weak financial performance (large ongoing losses and significant cash burn) and bearish technicals (price below major moving averages with negative MACD). Offsetting these risks, the latest earnings call was a clear positive with upgraded revenue guidance, a sharp gross-margin improvement, and an extended cash runway, supporting a mid-range overall score despite continued execution and funding risks.
Positive Factors
Commercial Revenue Growth
Rapidly increasing AUCATZYL revenue indicates meaningful commercial adoption and expanding demand rather than a purely development-stage business. Higher sales provide a growing base to absorb fixed costs, support investment in the pipeline, and improve the potential for operating leverage over the next several quarters.
Negative Factors
Persistent Losses and Cash Burn
Autolus remains dependent on substantial external funding because operating activities continue to consume significant cash and the company has not reached profitability. Persistent losses reduce financial flexibility and make successful revenue growth, margin expansion, and disciplined spending essential to sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial Revenue Growth
Rapidly increasing AUCATZYL revenue indicates meaningful commercial adoption and expanding demand rather than a purely development-stage business. Higher sales provide a growing base to absorb fixed costs, support investment in the pipeline, and improve the potential for operating leverage over the next several quarters.
Read all positive factors
Autolus Therapeutics (AUTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$441.82M
Dividend YieldN/A
Average Volume (3M)1.66M
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue Growth287.93%
EPS Growth-21.91%
CountryUS
Employees752
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.06
Shares Outstanding266,162,540
10 Day Avg. Volume1,869,220
30 Day Avg. Volume1,659,032
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.70
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue5.03
Enterprise Value/Gross Profit32.13
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$7.70Price Target Upside226.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$149.40M
Autolus Therapeutics Business Overview & Revenue Model
Company Description
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene a...
How the Company Makes Money
As a clinical-stage company, Autolus has historically not generated material recurring revenue from commercial product sales because its lead programs have been in development prior to broad commercial launch; therefore, detailed product-sales-bas...
Autolus Therapeutics Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.Positive Updates
Strong Quarter-over-Quarter Revenue Growth
Net product revenue of $45.7M in Q2 2026, up from $26.2M in Q1 2026 (approximately +74% QoQ) and up from $20.9M in Q2 2025 (approximately +119% YoY). First-half 2026 net revenue reached $71.9M, approaching full-year revenue from the first year of launch.
Negative Updates
Continued Net Loss and Operating Deficit
Despite improvement, company remains unprofitable: loss from operations of $43.8M and net loss of $39.1M in Q2 2026. Profitability for the overall company has not yet been achieved.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Quarter-over-Quarter Revenue Growth
Net product revenue of $45.7M in Q2 2026, up from $26.2M in Q1 2026 (approximately +74% QoQ) and up from $20.9M in Q2 2025 (approximately +119% YoY). First-half 2026 net revenue reached $71.9M, approaching full-year revenue from the first year of launch.
Read all positive updates
Company Guidance
Autolus upgraded full‑year AUCATZYL net product revenue guidance to $140–$150M (from a prior $120–$135M) after reporting Q2 net product revenue of $45.7M (Q1 $26.2M) and H1 revenue of $71.9M (close to last year’s full‑year launch total); gross margin stepped up to 55% in Q2 (from 6% in Q1 and negative in 2025) with a target mature ALL gross margin of 65–70% within ~12–18 months, Q2 cost of sales was $20.5M, R&D $27.9M, SG&A $41.2M, loss from operations $43.8M and net loss $39.1M (vs. $61.2M and $47.9M in Q2 2025); cash and marketable securities were $201.6M at June 30 (excluding a July $75M initial draw under a $250M facility with an extra $25M available for 6 months and up to $150M contingent tranches), and combined with anticipated net revenues plus the first two tranches (~$100M) the company expects runway into Q2 2028; commercial footprint is >80 U.S. centers (projected 90+ by year‑end) and ~20 U.K. centers by year‑end; key near‑term catalysts include CARLYSLE (ACR year‑end), FELIX analyses and AUTO8 initial data by year‑end, BOBCAT first 12‑patient data in Q1 2027 and 18‑patient readout H2 2027, CATULUS pediatric enrollment completion by end‑2027 with pivotal data by end‑2027 and potential filing end‑2027/early‑2028, and LUMINA Phase II data in 2028.Autolus Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
35
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 117.35M | 75.56M | 10.12M | 1.70M | 6.19M | 1.51M |
| Gross Profit | 18.38M | -21.03M | -130.90M | 1.70M | 6.19M | 1.51M |
| EBITDA | -220.89M | -250.28M | -233.07M | -156.77M | -132.24M | -132.47M |
| Net Income | -280.03M | -288.20M | -220.66M | -208.38M | -148.84M | -142.10M |
Balance Sheet | ||||||
| Total Assets | 493.23M | 589.07M | 782.73M | 375.38M | 490.27M | 405.56M |
| Cash, Cash Equivalents and Short-Term Investments | 201.63M | 300.71M | 588.02M | 239.57M | 382.44M | 310.34M |
| Total Debt | 83.51M | 351.59M | 52.63M | 52.97M | 24.26M | 68.01M |
| Total Liabilities | 418.39M | 410.94M | 355.40M | 263.91M | 191.60M | 92.24M |
| Stockholders Equity | 74.84M | 178.13M | 427.32M | 111.47M | 298.67M | 313.32M |
Cash Flow | ||||||
| Free Cash Flow | -237.45M | -310.70M | -241.09M | -156.57M | -123.15M | -126.72M |
| Operating Cash Flow | -225.61M | -283.57M | -206.27M | -145.59M | -112.31M | -117.86M |
| Investing Cash Flow | 286.14M | 158.46M | -394.55M | -10.99M | -10.84M | -8.86M |
| Financing Cash Flow | -7.77M | -4.34M | 589.55M | -883.00K | 223.61M | 284.06M |
Autolus Therapeutics Technical Analysis
Negative
2.36
Price Trends
2.00
Negative
1.81
Negative
1.67
Negative
Market Momentum
-0.10
Positive
36.15
Neutral
29.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Negative. The current price of 2.36 is above the 20-day moving average (MA) of 1.75, above the 50-day MA of 2.00, and above the 200-day MA of 1.67, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 36.15 is Neutral, neither overbought nor oversold. The STOCH value of 29.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AUTL.
Autolus Therapeutics Risk Analysis
Autolus Therapeutics disclosed 88 risk factors in its most recent earnings report. Autolus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Autolus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $441.82M | -1.53 | -178.58% | ― | 287.93% | -21.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $246.83M | -1.97 | -65.08% | ― | -23.36% | 27.52% | |
47 Neutral | $459.50M | -1.99 | -50.04% | ― | ― | 40.16% | |
45 Neutral | $296.96M | -1.55 | -52.76% | ― | -100.00% | -219.52% | |
42 Neutral | $125.34M | -1.11 | -39.64% | ― | ― | -6.70% | |
41 Neutral | $320.72M | -1.96 | -53.86% | ― | ― | -7.24% |
* Healthcare Sector Average
AUTL
Autolus Therapeutics
1.58
0.08
5.33%
FATE
Fate Therapeutics
2.09
0.57
37.50%
ALLO
Allogene Therapeutics
1.25
0.04
3.31%
NKTX
Nkarta
1.74
-0.52
-23.01%
IPSC
Century Therapeutics
1.58
0.99
167.80%
ARTV
Artiva Biotherapeutics, Inc.
6.20
1.36
28.10%
Autolus Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Autolus Lifts 2026 Guidance as AUCATZYL Sales Surge
Positive
Aug 11, 2026
In the quarter ended June 30, 2026, Autolus Therapeutics reported net product revenue of $45.7 million from AUCATZYL, up 119% year-on-year, supported by growing demand, additional treatment centers and early UK sales, while gross margin improved t...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Autolus Raises AUCATZYL Outlook, Secures New Credit Facility
Positive
Aug 3, 2026
Autolus Therapeutics raised its full-year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million on August 3, 2026, after reporting preliminary second-quarter AUCATZYL sales of about $45 million and a year-to-date gross mar...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Autolus Secures New $250 Million Financing and Warrants
Positive
Aug 3, 2026
Autolus Therapeutics entered into a senior secured notes facility with Perceptive Credit Holdings on July 30, 2026, providing up to $250 million in funding, including an initial $75 million tranche and three additional tranches contingent on futur...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.